Despite promising results of the phase I and randomized phase II trial, the combination of olaratumab with doxorubicin in patients with advanced STS failed to achieved a highly significant improvement of outcome in the recent phase III trial ‘ANNOUNCE’. 13 In the era of targeted therapies, uncovering biomarkers of activity and improving knowledge in mechanisms of resistance are crucial to overcome the current challenges.
← all excerpts
Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas.
1
—
—